OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

The market supports treatment for growth hormone deficiencies and anti-aging therapies. Biosimilar development enhances accessibility. Human Growth Hormone Market report furnishes invaluable ...

In December 2014, Pfizer and OPKO began an agreement to develop hGH-CTP for growth hormone deficiency in adults and children, and for children who are small for gestational age and fail to show ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going ... the receptors for an appetite- and blood sugar-reducing hormone called GLP-1. But the company was "looking at ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Additionally, Pfizer’s strategic focus on obesity treatments, despite cautious expectations for danuglipron, remains a significant growth area. The company’s robust acquisitions strategy ...

Pfizer said Tuesday. The company also cited sales growth from several other drugs, as total revenue climbed 31% to $17.7 billion in the recently completed quarter. Adjusted earnings totaled $1.06 ...

Despite normal hormone levels in her blood tests ... 4 No formal studies have established a link between breast parenchymal growth and the Pfizer COVID-19 vaccine. Although these social media ...